KEGG pathway analysis further highlighted that these targets contribute to EGFR TKI resistance, ErbB signaling, PI3K‐Akt, and VEGF pathways, all of which are implicated in HCC aggressiveness and therapeutic resistance [54, 55, 56, 57]. Here, AKT1 is linked to hepatocellular carcinoma.